PMID- 18712052
OWN - NLM
STAT- MEDLINE
DCOM- 20081002
LR  - 20181201
IS  - 0916-9636 (Print)
IS  - 0916-9636 (Linking)
VI  - 31
IP  - 5
DP  - 2008 May
TI  - Effects of rosiglitazone (a peroxysome proliferator-activated receptor gamma 
      agonist) on the blood pressure and aortic structure in metabolically programmed 
      (perinatal low protein) rats.
PG  - 965-75
LID - 10.1291/hypres.31.965 [doi]
AB  - This study investigated the effects of rosiglitazone on nutritionally programmed 
      chronic disease, with a focus on blood pressure (BP) and aortic wall structural 
      remodeling. Wistar pregnant rats were fed one of two diets: a normal protein diet 
      (19% protein; NP rats) or low-protein diet (5% protein; LP rats). Male offspring 
      at 3 months of age were randomly divided into four groups: NP offspring treated 
      with rosiglitazone (NPR); untreated NP offspring (NP); LP offspring treated with 
      rosiglitazone (LPR); untreated LP offspring (LP). Rosiglitazone was administered 
      at a dose of 5 mg/kg/d until 6 months of age. BP was elevated in LP offspring. 
      Rosiglitazone reduced BP beginning in the first week of treatment in the LPR 
      offspring. The insulin sensitivity was increased in LP offspring, and was not 
      altered by rosiglitazone. LP offspring exhibited a 40% reduction in the amount of 
      elastic fibers in the aorta wall compared with NP offspring (p < 0.01), and the 
      quantity of elastic fibers was not altered by rosiglitazone. The smooth muscle 
      cells, elastic lamellae, circumferential wall tension (CWT) and tensile stress 
      (TS) were increased in LP offspring, indicating increased blood flow in the 
      aorta. Rosiglitazone reduced both CWT and TS by 30% compared to the levels in 
      untreated LP offspring (p < 0.01 for both). Rosiglitazone restored the 
      expressions of angiotensin II type 1 receptor and endothelial nitric oxide 
      synthase nearly to the levels in the NP offspring. ANOVA disclosed a significant 
      two-factor interaction between protein content in the diet and rosiglitazone 
      treatment (p < 0.001 for CWT and p < 0.00001 for TS, two-way ANOVA). We conclude 
      that rosiglitazone has beneficial effects in reducing the BP and the aortic 
      tunica media hypertrophy with consequent balance of the wall stress in 
      metabolically programmed offspring.
FAU - Torres, Thiago da Silva
AU  - Torres TS
AD  - Laboratory of Morphometry and Cardiovascular Morphology, Biomedical Center, 
      Institute of Biology, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - D'Oliveira Silva, Geraldo
AU  - D'Oliveira Silva G
FAU - Aguila, Marcia Barbosa
AU  - Aguila MB
FAU - de Carvalho, Jorge Jose
AU  - de Carvalho JJ
FAU - Mandarim-De-Lacerda, Carlos A
AU  - Mandarim-De-Lacerda CA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hypertens Res
JT  - Hypertension research : official journal of the Japanese Society of Hypertension
JID - 9307690
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 0 (Leptin)
RN  - 0 (PPAR gamma)
RN  - 0 (Receptor, Angiotensin, Type 1)
RN  - 0 (Thiazolidinediones)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
SB  - IM
MH  - Animals
MH  - Aorta/*drug effects/metabolism/pathology
MH  - Blood Glucose/metabolism
MH  - Blood Pressure/*drug effects/physiology
MH  - Carbohydrate Metabolism
MH  - Diet, Protein-Restricted/*adverse effects
MH  - Disease Models, Animal
MH  - Elasticity
MH  - Female
MH  - Hypertension/etiology/physiopathology/prevention & control
MH  - Hypertrophy/etiology/pathology/prevention & control
MH  - Insulin/blood
MH  - Leptin/blood
MH  - Male
MH  - Nitric Oxide Synthase Type III/metabolism
MH  - PPAR gamma/*agonists
MH  - Pregnancy
MH  - Prenatal Exposure Delayed Effects/*etiology/physiopathology/*prevention & control
MH  - Rats
MH  - Rats, Wistar
MH  - Receptor, Angiotensin, Type 1/metabolism
MH  - Rosiglitazone
MH  - Thiazolidinediones/*pharmacology
MH  - Tunica Media/drug effects/pathology
EDAT- 2008/08/21 09:00
MHDA- 2008/10/03 09:00
CRDT- 2008/08/21 09:00
PHST- 2008/08/21 09:00 [pubmed]
PHST- 2008/10/03 09:00 [medline]
PHST- 2008/08/21 09:00 [entrez]
AID - 10.1291/hypres.31.965 [doi]
PST - ppublish
SO  - Hypertens Res. 2008 May;31(5):965-75. doi: 10.1291/hypres.31.965.